Edwards Lifesciences (NYSE: EW) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Edwards Lifesciences met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. GAAP earnings per share grew significantly.

Margins expanded across the board.

Revenue details
 Edwards Lifesciences logged revenue of $517.2 million. The 21 analysts polled by S&P Capital IQ looked for revenue of $514.2 million on the same basis. GAAP reported sales were 7.3% higher than the prior-year quarter's $482.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.82. The 24 earnings estimates compiled by S&P Capital IQ averaged $0.76 per share. GAAP EPS of $0.82 for Q2 were 44% higher than the prior-year quarter's $0.57 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 75.8%, 270 basis points better than the prior-year quarter. Operating margin was 23.6%, 370 basis points better than the prior-year quarter. Net margin was 18.2%, 410 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $493.7 million. On the bottom line, the average EPS estimate is $0.66.

Next year's average estimate for revenue is $2.05 billion. The average EPS estimate is $3.06.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 162 members out of 215 rating the stock outperform, and 53 members rating it underperform. Among 67 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 52 give Edwards Lifesciences a green thumbs-up, and 15 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $77.00.

Is Edwards Lifesciences the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.